Privium Fund Management B.V. Uro Gen Pharma Ltd. Transaction History
Privium Fund Management B.V.
- $436 Million
- Q4 2024
A detailed history of Privium Fund Management B.V. transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Privium Fund Management B.V. holds 27,691 shares of URGN stock, worth $293,247. This represents 0.07% of its overall portfolio holdings.
Number of Shares
27,691Holding current value
$293,247% of portfolio
0.07%Shares
1 transactions
Others Institutions Holding URGN
# of Institutions
133Shares Held
36.1MCall Options Held
22KPut Options Held
93.8K-
Rtw Investments, LP New York, NY3.79MShares$40.1 Million0.77% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.74MShares$39.6 Million0.09% of portfolio
-
Menora Mivtachim Holdings Ltd.2.3MShares$24.4 Million0.19% of portfolio
-
Black Rock Inc. New York, NY2.19MShares$23.2 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.18MShares$23.1 Million0.0% of portfolio
About UroGen Pharma Ltd.
- Ticker URGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 22,740,500
- Market Cap $241M
- Description
- UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...